Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.47 |
| ▸ | FAAH | O00519 | 6/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ICMT | O60725 | 1/20 | 0.42 |
| ▸ | ALB | P02768 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6754891 | 0.85 | MEN1 (0.51) | ATMTDP1L3MBTL1ZDHHC2FAAH | |
| SCHEMBL11252540 | 0.85 | ACHE (0.52) | ATMTDP1L3MBTL1ZDHHC2FAAH | |
| SCHEMBL11713330 | 0.83 | NPC1 (0.45) | ZDHHC2FAAHNPC1RAB9AALDH1A1 | |
| SCHEMBL9373248 | 0.80 | MEN1 (0.46) | ZDHHC2FAAHMEN1KMT2ANPC1 | |
| SCHEMBL4854943 | 0.80 | ACHE (0.52) | ATMTDP1L3MBTL1MEN1KMT2A | |
| SCHEMBL9160789 | 0.79 | MEN1 (0.45) | ZDHHC2FAAHMEN1KMT2ALMNA | |
| SCHEMBL22450141 | 0.79 | MEN1 (0.61) | ATMTDP1L3MBTL1MEN1KMT2A | |
| SCHEMBL6024380 | 0.79 | ATM (0.46) | ATMTDP1L3MBTL1ZDHHC2FAAH | |
| SCHEMBL14378047 | 0.78 | LMNA (0.38) | ATMTDP1L3MBTL1ZDHHC2FAAH | |
| SCHEMBL11431750 | 0.78 | ZDHHC2 (0.45) | ZDHHC2FAAHNPC1RAB9AJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6743755-B2 | HERBICIDAL COMPOSITION WHICH HAS A CONTENT OF AT LEAST ONE N-ARYL NITROGEN-CONTAINING HETEROCYCLIC COMPOUND OF THE GENERAL METHOD OF COMBATING UNDESIRABLE PLANTS WHICH COMPRISES ALLOWING AN N-ARYL NITROGEN-CONTAINING HETEROCYCLIC | BAYER AKTIENGESELLSCHAFT (DE) | 2004-06-01 | — | — | US | disclosed |
| US-20030208073-A1 | Substituted N-aryl nitrogen-containing heterocyclic compounds | LINKER KARL-HEINZ (DE) | 2003-11-06 | — | — | US | disclosed |
| US-20030144522-A1 | Substituted N-aryl nitrogen-containing heterocyclic compounds | LINKER KARL-HEINZ (DE) | 2003-07-31 | — | — | US | disclosed |
| US-6426318-B1 | KILLING WEEDS | BAYER AKTIENGESELLSCHAFT (DE) | 2002-07-30 | — | — | US | disclosed |
| US-6162765-A | Substituted N-aryl nitrogen-containing heterocyclic compounds | BAYER AKTIENGESELLSCHAFT (DE) | 2000-12-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030208073-A1 | Substituted N-aryl nitrogen-containing heterocyclic compounds | NAT1, CYP1B1, CYP1A1 | ATM 3027/4885TDP1 2064/4885L3MBTL1 3862/4885 |
| US-20030144522-A1 | Substituted N-aryl nitrogen-containing heterocyclic compounds | NAT1, CYP1B1, CYP1A1 | ATM 3027/4885TDP1 2064/4885L3MBTL1 3862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.